Justin C. Dodson

Array ( [id] => 17343970 [patent_doc_number] => 20220010301 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => METHODS OF SELECTING FUNCTIONAL INTERFACE MIMICS, AND COMPOSITIONS THEREOF [patent_app_type] => utility [patent_app_number] => 17/294345 [patent_app_country] => US [patent_app_date] => 2019-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20790 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17294345 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15895313 [patent_doc_number] => 20200147175 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => METHOD FOR TREATING ANTI-HER2 THERAPY-RESISTANT MUC4+ HER2+ CANCER [patent_app_type] => utility [patent_app_number] => 16/679272 [patent_app_country] => US [patent_app_date] => 2019-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16679272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18056444 [patent_doc_number] => 20220387530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => ONCOLYTIC VIROTHERAPY AND IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/775203 [patent_app_country] => US [patent_app_date] => 2019-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46032 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17775203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17297914 [patent_doc_number] => 20210393753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => FGL2 NEUTRALING CELL THERAPY AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/291303 [patent_app_country] => US [patent_app_date] => 2019-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14966 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -89 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17291303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292257 [patent_doc_number] => 20210388096 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => ANTI-HUMAN Fn14 ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/290180 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13534 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17337441 [patent_doc_number] => 20220003772 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => METHODS OF TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/289389 [patent_app_country] => US [patent_app_date] => 2019-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12846 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299945 [patent_doc_number] => 20210395784 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => CRISPR/CAS12F ENZYME AND SYSTEM [patent_app_type] => utility [patent_app_number] => 17/289204 [patent_app_country] => US [patent_app_date] => 2019-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13399 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15797293 [patent_doc_number] => 20200121789 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => COMBINATION IMMUNOTHERAPY FOR TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER [patent_app_type] => utility [patent_app_number] => 16/658047 [patent_app_country] => US [patent_app_date] => 2019-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17477 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16658047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19650069 [patent_doc_number] => 12171829 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-24 [patent_title] => Abituzumab for the treatment of colorectal cancer [patent_app_type] => utility [patent_app_number] => 16/657828 [patent_app_country] => US [patent_app_date] => 2019-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 36535 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16657828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17200137 [patent_doc_number] => 20210340232 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => MONOCLONAL ANTIBODIES AGAINST HUMAN DICKKOPF3 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/285470 [patent_app_country] => US [patent_app_date] => 2019-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31545 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299553 [patent_doc_number] => 20210395392 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => ANTI-MERTK ANTIBODIES FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/284119 [patent_app_country] => US [patent_app_date] => 2019-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28200 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17284119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19379384 [patent_doc_number] => 20240269254 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => Combination Therapy for Treating Cancer with an Intravenous Administration of a Recombinant MVA and an Immune Checkpoint Antagonist or Agonist [patent_app_type] => utility [patent_app_number] => 17/282774 [patent_app_country] => US [patent_app_date] => 2019-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22850 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17282774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343672 [patent_doc_number] => 20240252635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTI-CD37 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/281724 [patent_app_country] => US [patent_app_date] => 2019-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35504 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17281724 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15342601 [patent_doc_number] => 20200009192 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => THERAPEUTIC APOPTOTIC CELLS FOR CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 16/576734 [patent_app_country] => US [patent_app_date] => 2019-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16576734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19840330 [patent_doc_number] => 12252702 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Recombinant poxviruses for cancer immunotherapy [patent_app_type] => utility [patent_app_number] => 17/275974 [patent_app_country] => US [patent_app_date] => 2019-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 581 [patent_figures_cnt] => 416 [patent_no_of_words] => 112496 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17275974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16977991 [patent_doc_number] => 20210222228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => PLK1 TARGET PHOSPHORYLATION STATUS AND TREATMENT OF CANCER WITH PLK1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/271500 [patent_app_country] => US [patent_app_date] => 2019-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5633 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -59 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18871196 [patent_doc_number] => 11858982 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-02 [patent_title] => Cancer treatment with an antibody [patent_app_type] => utility [patent_app_number] => 17/266883 [patent_app_country] => US [patent_app_date] => 2019-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 21 [patent_no_of_words] => 18216 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17266883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15496351 [patent_doc_number] => 20200048364 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => RECOMBINANT BIFUNCTIONAL PROTEIN TARGETING CD47 AND HER2 [patent_app_type] => utility [patent_app_number] => 16/535075 [patent_app_country] => US [patent_app_date] => 2019-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16535075 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20106992 [patent_doc_number] => 12357690 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-15 [patent_title] => Epitope of EPB41L5, and monoclonal antibody [patent_app_type] => utility [patent_app_number] => 17/265755 [patent_app_country] => US [patent_app_date] => 2019-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 38 [patent_no_of_words] => 8530 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17265755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15365983 [patent_doc_number] => 20200018756 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => BIOMARKERS FOR DISEASE PROGRESSION IN MELANOMA [patent_app_type] => utility [patent_app_number] => 16/526694 [patent_app_country] => US [patent_app_date] => 2019-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9825 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16526694 [rel_patent_id] =>[rel_patent_doc_number] =>)